Early Detection Research Network


This biomarker is also known as:
  • MEK 1,
  • MAP kinase kinase 1,
  • MAP2K1,
  • MKK1,
  • ERK activator kinase 1,
  • EC,
  • mitogen-activated protein kinase kinase 1,
  • MAPK/ERK kinase 1,
  • MEK1,
  • protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1),
  • MAPKK 1,
  • PRKMK1,
  • dual specificity mitogen-activated protein kinase kinase 1,
  • MAPKK1,


MAP2K1, or mitogen-activated protein kinase kinase 1, is a dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals. MAP2K1 is located upstream of MAP kinases and stimulates the enzymatic activity of MAP kinases upon wide variety of extra- and intracellular signals. MAP2K1 is thought to be involved in binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors, as well as cellular processes such as proliferation, differentiation, transcription regulation and development.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein

The following organs have data associated with this biomarker…


Phase: Two
QA State: Under Review


No additional breast data available.

Performance Comment

MAP2K1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.